Search

Your search keyword '"López-Campos F"' showing total 147 results
Start Over Author "López-Campos F"
147 results on '"López-Campos F"'

4. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

Author

Subiela, J.D., Gomis Sellés, E., Maldonado, A., Lopez Campos, F., Aumatell Ovide, J., Ajuria Illarramendi, O., González-Padilla, D.A., Gajate, P., Ortega Polledo, L.E., Alonso y Gregorio, S., Guerrero-Ramos, F., Gómez Dos Santos, V., Rodríguez-Patrón, R., Calais, J., Kishan, A.U., Burgos Revilla, F.J., and Couñago, F.

Published
2023
Full Text
View/download PDF

8. PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial

Author

Zilli, T., primary, Shankar, S., additional, Brabrand, S., additional, Dirix, S., additional, Liefhooghe, S., additional, Otte, F-X., additional, Gomez-Iturriaga, A., additional, Everaerts, W., additional, Shelan, M., additional, Conde-Moreno, A., additional, López Campos, F., additional, Papachristofilou, A., additional, Guckenberger, M., additional, Scorsetti, M., additional, Zapatero, A., additional, Villafranca Iturre, A.E., additional, Eito, C., additional, Counago, F., additional, Muto, P., additional, Van De Voorde, L., additional, Mach, N., additional, Fonteyne, V., additional, Dries, R., additional, and Ost, P., additional

Published
2024
Full Text
View/download PDF

9. Terapia trimodal: ¿el nuevo tratamiento estándar para el tumor vesical músculo-inavasor?

Author

López Valcárcel, M., primary, Barrado Los Arcos, M., additional, Ferri Molina, M., additional, Cienfuegos Belmonte, I., additional, Duque Santana, V., additional, Gajate Borau, P., additional, Fernández Ibiza, J., additional, Álvarez Maestro, M., additional, Sargos, P., additional, López Campos, F., additional, and Couñago Lorenzo, F., additional

Published
2024
Full Text
View/download PDF

10. Is achieving undetectable PSA (uPSA) a prognostic factor for improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified treatments?

Author

Puente, J., primary, López Campos, F., additional, Ohlmann, C., additional, Ríos, E., additional, Santoni, M., additional, Diels, J., additional, Cabrieto, J., additional, Egea, M., additional, Quesada, A., additional, Calderón, J.M., additional, and Birtle, A., additional

Published
2023
Full Text
View/download PDF

13. How does PSMA PET/CT influence the management of prostate cancer patients?

Author

Minguez Ojeda, C.S., primary, Garcia Barreras, S., additional, Hervás Morón, A., additional, Ajuria Illaramendi, O., additional, Tagalos Munoz, A., additional, Mata Alcaraz, M., additional, López Pérez, E., additional, Fernandez Conejo, G., additional, Sanz Mayayo, E., additional, Rodriguez- Patrón, R., additional, López Campos, F., additional, and Burgos Revilla, F.J., additional

Published
2023
Full Text
View/download PDF

15. To the editor, response letter

Author

Conde-Moreno, A. J., Zucca , D., Pérez-Calatayud, M. J., López-Campos, F., Celada , F., Rubio , C., Fernández-Letón, P., Gómez-Caamaño, A., Guirado , D., and Contreras , J.

Published
2021
Full Text
View/download PDF

16. PO-2037 Hydrogel Spacer in the treatment of prostate cancer: Feasibility and Rectal Dosimetry

Author

Domínguez Rullán, J.A., primary, Valero Perena, M., additional, Centelles Hidalgo, E., additional, Mesa López, F., additional, López Campos, F., additional, Muñoz Miguelañez, M.T., additional, Vallejo Ocaña, C., additional, Sevillano García, D., additional, García Fuentes, J.D., additional, Sancho García, S., additional, and Hervás Morón, A., additional

Published
2023
Full Text
View/download PDF

17. Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?

Author

Carrasco-Esteban, E., primary, Barrionuevo-Castillo, P., additional, Domínguez-Rullán, J., additional, Gómez-Aparicio, M.A., additional, Ferri-Molina, M., additional, Sáez-Bueno, P., additional, Zalabarría-Zarrabeitia, Z., additional, Scorsetti, M., additional, Arcangeli, S., additional, López-Campos, F., additional, and Couñago, F., additional

Published
2022
Full Text
View/download PDF

18. OC-0603 PEACE V – STORM randomized phase II trial for oligorecurrent nodal prostate cancer: acute toxicity

Author

Zilli, T., primary, Siva, S., additional, Heikkilä, R., additional, Dirix, P., additional, Liefhooghe, N., additional, Otte, F., additional, Gomez-Iturriaga, A., additional, Everaerts, W., additional, Shelan, M., additional, Conde- Moreno, A., additional, López Campos, F., additional, Papachristofilou, A., additional, Guckenberger, M., additional, Scorsetti, M., additional, Zapatero, A., additional, Villafranca Iturre, A., additional, Eito, C., additional, Couñago, F., additional, Muto, P., additional, Van De Voorde, L., additional, Fonteyne, V., additional, Moon, D., additional, Thon, K., additional, Mercier, C., additional, Achard, V., additional, Stellamans, K., additional, Goetghebeur, E., additional, Reynders, D., additional, and Ost, P., additional

Published
2022
Full Text
View/download PDF

19. PO-1704 Dosimetric effect of uncorrected rotational errors during prostate SBRT Cyberknife treatments.

Author

Sevillano, D., primary, García-Fuentes, J.D., additional, Hervás, A., additional, Vallejo, C., additional, López-Campos, F., additional, Colmenares, R., additional, Morís, R., additional, Capuz, B., additional, Cámara, M., additional, Retorta, P., additional, Galiano, P., additional, Williamson, S., additional, Béjar, M.J., additional, Prieto, D., additional, and García-Vicente, F., additional

Published
2022
Full Text
View/download PDF

20. OC-0608 Phase II trial of hypofractionated postoperative radiotherapy in prostate cancer: NCT02192788

Author

Hervás, A., primary, Zapatero, A., additional, Carballo, A.M., additional, Barrado, M., additional, López-Campos, F., additional, Cano, C., additional, Martin de Vidales, C., additional, Rodríguez, A., additional, Eito, C., additional, Salinas, A., additional, Peleteiro, P., additional, Visus, I., additional, Rodríguez Melcón, I., additional, Vázquez, G., additional, Lazo, A., additional, Couñago, F., additional, Guerrero, L., additional, Otero, A., additional, Vasquez, W.A., additional, Samper, P., additional, Caballero, B., additional, Sancho, G., additional, Pérez, R., additional, Olivera, J., additional, and del Rey, A., additional

Published
2022
Full Text
View/download PDF

21. PO-1394 Adjuvant radiation therapy after radical prostatectomy

Author

Duque Santana, V., primary, Domínguez Rullán, J., additional, Hervás Morón, A., additional, López-Campos, F., additional, Vallejo Ocaña, C., additional, Valero Perena, M., additional, Martín Martín, M., additional, Sevillano Martínez, D., additional, Garcia Fuentes, J.D., additional, and Sancho García, S., additional

Published
2022
Full Text
View/download PDF

22. PD-0405 Analysis of the internal motion of the urethra caused by urethral catheters

Author

Sevillano, D., primary, Hervás, A., additional, Rodríguez-Patrón, R., additional, García-Fuentes, J.D., additional, Colmenares, R., additional, Vallejo, C., additional, López-Campos, F., additional, Domínguez-Rullán, J.A., additional, Muñoz, T., additional, Cámara, M., additional, Capuz, B., additional, Morís, R., additional, Galiano, P., additional, Retorta, P., additional, Williamson, S., additional, Béjar, M.J., additional, Prieto, D., additional, and García-Vicente, F., additional

Published
2022
Full Text
View/download PDF

24. PO-1132 Clinical outcomes after radiosurgery in vestibular schwannomas

Author

Vázquez Barreiro, B., primary, López Campos, F., additional, Vázquez de la Torre González, M.L., additional, Caeiro Muñoz, M., additional, Ochagavía Galilea, V., additional, Nieto Regueira, I., additional, Naranjo Sánchez, M.A., additional, Gonzalez Rodríguez, M., additional, Azevedo González, E., additional, Vázquez Rodríguez, J., additional, González Pose, A., additional, and Muñoz Garzón, V., additional

Published
2022
Full Text
View/download PDF

25. PO-1712 Oligorecurrent nodal prostate cancer: radiotherapy QA of the randomized PEACE V-STORM phase II trial

Author

Achard, V., primary, Heikkilä, R., additional, Dirix, P., additional, Siva, S., additional, Liefhooghe, N., additional, Conde-Moreno, A., additional, Meersschout, S., additional, Muto, P., additional, Eíto, C., additional, Barrado, M., additional, Putora, P.M., additional, Zwhalen, D., additional, Scorsetti, M., additional, Zapatero, A., additional, Van De Voorde, L., additional, López Campos, F., additional, Couñago, F., additional, Vanhoutte, F., additional, Jaccard, M., additional, Dipasquale, G., additional, Ost, P., additional, and Zilli, T., additional

Published
2021
Full Text
View/download PDF

28. Recommended procedures and responsibilities for radiosurgery (SRS) and extracranial stereotactic body radiotherapy (SBRT): report of the SEOR in collaboration with the SEFM

Author

Conde-Moreno AJ, Zucca Aparicio D, Pérez-Calatayud MJ, López-Campos F, Celada Álvarez F, Rubio Rodríguez C, Fernández-Letón P, Gómez-Caamaño A, and Contreras Martínez J

Subjects
Neoplasms, Humans, Extracranial Stereotactic Body Radiotherapy, Medical Physicist, Oncologist, Radiation, Radiosurgery, SBRT, SRS, Radiosurgery
Abstract

Today, patient management generally requires a multidisciplinary approach. However, due to the growing knowledge base and increasing complexity of Medicine, clinical practice has become even more specialised. Radiation oncology is not immune to this trend towards subspecialisation, which is particularly evident in ablative radiotherapy techniques that require high dose fractions, such as stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT). The aim of the present report is to establish the position of the Spanish Society of Radiation Oncology (SEOR), in collaboration with the Spanish Society of Medical Physics (SEFM), with regard to the roles and responsibilities of healthcare professionals involved in performing SRS and SBRT. The need for this white paper is motivated due to the recent changes in Spanish Legislation (Royal Decree [RD] 601/2019, October 18, 2019) governing the use and optimization of radiotherapy and radiological protection for medical exposure to ionizing radiation (article 11, points 4 and 5) [1 ], which states: "In radiotherapy treatment units, the specialist in Radiation Oncology will be responsible for determining the correct treatment indication, selecting target volumes, determining the clinical radiation parameters for each volume, directing and supervising treatment, preparing the final clinical report, reporting treatment outcomes, and monitoring the patient's clinical course." Consequently, the SEOR and SEFM have jointly prepared the present document to establish the roles and responsibilities for the specialists-radiation oncologists (RO), medical physicists (MP), and related staff -involved in treatments with ionizing radiation. We believe that it is important to clearly establish the responsibilities of each professional group and to clearly establish the professional competencies at each stage of the radiotherapy process.

Published
2020

29. PO-1557 RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

Author

Alvarez, A., Valduvieco, I., Arance, A., Delgado, R., Berciano, M.A., López Campos, F., Soria, A., Romero, J.L., Sánchez Mauriño, P., Lucas, A., Martín Liberal, J., Prada, P.J., García Castaño, A., Alamo, M.C., Puertas, E., González Cao, M., Conde, A., Díaz Beveridge, R., Corona, J.A., Aguado, C., Foro, P., Vidal, J., López Soler, F., Cerezuela Fuentes, P., and Márquez Rodas, I.

Published
2023
Full Text
View/download PDF

32. Incidence of urological complications in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first line abiraterone and enzalutamide

Author

Lorca Alvaro, J., primary, Serrano Domingo, J.J., additional, Álvarez Rodriguez, S., additional, Alonso Gordoa, T., additional, López Campos, F., additional, Rodriguez-Patrón, R., additional, Gajate Borau, P., additional, Brasero Burgos, J., additional, Laso Garcia, I., additional, Carrato Mena, A., additional, and Burgos Revilla, F.J., additional

Published
2018
Full Text
View/download PDF

34. Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide

Author

López Campos, F., primary, Moreno, I., additional, Conde-Moreno, A., additional, Gómez-Iturriaga, A., additional, Ruiz Vico, M., additional, Romero Laorden, N., additional, Henríquez López, I., additional, Peleteiro Higuero, P., additional, Lozano Mejorada, R., additional, Piquer, T., additional, Couselo, M., additional, Gómez Ramos, J., additional, Navarro, J., additional, Barrionuevo Castillo, P., additional, García, R., additional, Villatoro, R., additional, Montesa, A., additional, Saez, M.I., additional, Herrera, B., additional, and Castro Marcos, E., additional

Published
2018
Full Text
View/download PDF

38. EP-1702: Stereotactic body radiotherapy for oligometastatic and oligoprogression patients

Author

De la Pinta Alonso, C., primary, Vallejo Ocaña, C., additional, Hernanz De Lucas, R., additional, Martín Martín, M., additional, Fernández-Lizarbe, E., additional, Martín Sánchez, M., additional, Domínguez Rullán, J., additional, Muñóz Migueláez, T., additional, López Campos, F., additional, Hervás Morón, A., additional, and Sancho Garcia, S., additional

Published
2018
Full Text
View/download PDF

39. EP-1654: Evaluation of tolerability in combined treatment with immune inhibitors and palliative radiotherapy

Author

De la Pinta Alonso, C., primary, Fernández-Lizarbe, E., additional, Martín Sánchez, M., additional, Domínguez-Rullán, J., additional, Hernánz De Lucas, R., additional, Vallejo Ocaña, C., additional, Martín Martín, M., additional, Barrionuevo, P., additional, Muñóz Migueláñez, T., additional, López Campos, F., additional, Hervás Morón, A., additional, and Sancho García, S., additional

Published
2018
Full Text
View/download PDF

40. 644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?

Author

Romero Laorden, N., Llacer Perez, C., Castro Marcos, E., Salles, D.C., Lozano Mejorada, R., Thorne, H., Aragon, I.M., Lopez Campos, F., Rubio Briones, J., Gutierrez Pecharromán, A.M., Prieto, J.D., Pacheco, M.I., Garces, T., Zambrana, F., Mateo, J., Lopez-Casas, P.P., Sandhu, S., Antonarakis, E.S., Olmos Hidalgo, D., and Lotan, T.

Published
2020
Full Text
View/download PDF

41. 612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study

Author

Lozano Mejorada, R., Castro Marcos, E., Aragon, I.M., Thorne, H., Lopez Campos, F., Sanz, A., Alonso, C., Anido, U., Juan Fita, M.J., Gutierrez Pecharromán, A.M., Ramirez-Backhaus, M., Balmana, J., Chirivella Gonzalez, I., Llort, G., Romero Laorden, N., Arevalo Lobera, S., Rubio Briones, J., Pritchard, C.C., Sandhu, S., and Olmos Hidalgo, D.

Published
2020
Full Text
View/download PDF

42. Small Cell Prostate Cancer: A Potential Prophylactic Treatment for a Rare and Aggressive Tumor

Author

ini D and López-Campos F

Subjects
PCA3, Oncology, medicine.medical_specialty, Prostatectomy, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Small-cell carcinoma, 03 medical and health sciences, Prostate cancer, Prostate-specific antigen, 0302 clinical medicine, medicine.anatomical_structure, Prostate, 030220 oncology & carcinogenesis, Internal medicine, Epidemiology of cancer, medicine, 030212 general & internal medicine, business
Abstract

Small cell prostate cancer (SCPC) is a rare pathology, with aggressive behaviour and a high tendency to metastasize. We present a case report of a 62-year-old male who underwent prostatectomy due to a rising prostate specific antigen (PSA) value and a positive biopsy for prostate cancer. Pathology results revealed a poorly differentiated adenocarcinoma of the prostate gland, Gleason score of 4+5=9, with extensive areas of undifferentiated small cell carcinoma. Despite aggressive adjuvant chemotherapy, hormone deprivation treatment and radiotherapy, the patient developed a castration-resistant prostate cancer with oligometastatic disease, diagnosed by choline positron emission tomography - computerized tomography (PET-CT). We discuss the clinical aspects correlated with this unusual subgroup of prostate cancer, adding a literature review to talk over potential prophylactic treatments in order to prevent central nervous system lesions, or potential discontinuation of hormone deprivation treatment if poor response is achieved.

Published
2016
Full Text
View/download PDF

43. EP-1320: Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer: Trial in progress

Author

Conde Moreno, A., primary, Lopez Torrecilla, J., additional, Pastor Peidro, J., additional, Hervás Morón, A., additional, López-Campos, F., additional, Mendez Villamón, A., additional, Puertas Valiño, M.M., additional, Sola Galarza, A., additional, Rico Oses, M., additional, Samper Ots, P., additional, Pérez-Romasanta, L.A., additional, Ibañez Villaoslada, C., additional, Valero Albarrán, J., additional, Ortiz Rodil, N., additional, García Piñon, F., additional, and Ferrer Albiach, C., additional

Published
2017
Full Text
View/download PDF

45. Phase II study of SBRT as treatment for oligometastases in prostate cancer (SBRT-SG 05): Trial in progress

Author

Conde, Moreno A.J., primary, López-Torrecilla, J., additional, Pastor, Peidró J., additional, Hervás, Morón A., additional, López-Campos, F., additional, Mendez, Villamón A., additional, Puerta, Valino M.M., additional, Rico, Oses M., additional, Sola, Galarza A., additional, Samper, Ots P., additional, Pérez-Romasanta, L.A., additional, Valero, Albarrán J., additional, Ibañez, Villaoslada C., additional, Ortiz, Rodil N., additional, and Ferrer, Albiach C., additional

Published
2016
Full Text
View/download PDF

46. Dolor irruptivo oncológico inducido por radioterapia: ¿es posible optimizar su tratamiento?

Author

Olay Gayoso, L., Rijo, G.J., Pozas de Celis, R., Antonini, O., Triana Martínez, G., López Muñoz, M., Monroy Antón, José Luis, López Campos, F., Alled Comín, L., Victoria Fernández, C., Rodríguez Sánchez, César Augusto, Ferrer Albiach, Carlos, Estornell Gualde, M. A., Lanzuela, M., Castro Gómez, José Enrique, Muñoz Garzón, Victor Manuel, Conde Moreno, Antonio José, Calvo Crespo, Patricia, Martínez Cedrés, J. C., Asín Felipe, Gemma, Olay Gayoso, L., Rijo, G.J., Pozas de Celis, R., Antonini, O., Triana Martínez, G., López Muñoz, M., Monroy Antón, José Luis, López Campos, F., Alled Comín, L., Victoria Fernández, C., Rodríguez Sánchez, César Augusto, Ferrer Albiach, Carlos, Estornell Gualde, M. A., Lanzuela, M., Castro Gómez, José Enrique, Muñoz Garzón, Victor Manuel, Conde Moreno, Antonio José, Calvo Crespo, Patricia, Martínez Cedrés, J. C., and Asín Felipe, Gemma

Abstract

Introduction: In the context of radiotherapy, control of breakthrough cancer pain (BTPc) is particularly challenging. BTPc has been defined by the Spanish Society of Pain (SED), the Spanish Society of Medical Oncology (SEOM) and the Spanish Society for Palliative Care (SECPAL) as a sudden and transient exacerbation of pain of great intensity (VAS > 7) and short (less than 20-30 minutes), which appears on the basis of a stable persistent pain when it is reduced to a tolerable level (VAS < 5) by using major opioids. Objectives: The main objective of this study was to assess the intensity of BTPc induced by cancer treatments that included radiotherapy (RT), both exclusive and associated with chemotherapy (RT/CT). Secondly, the efficacy of treatment was evaluated with fentanyl sublingual scheduled for BTPc control. Material and methods: Retrospective, observational study in 110 patients recruited in 19 Spanish Radiotherapy Services. Patients must have BTPc induced by RT or RT/CT, with or without medication prescribed and with an intensity outside a VAS > 6 in the last 24-48 h. Controls were established at baseline and at 3, 7, 15 and 30 days. Results: There was a decrease in mean values ??on the VAS scale as the study progressed (VAS = 6 in the control 0 to VAS = 3 in the control 3) and the differences were significant (p < 0.0001). Treatment satisfaction was rated as good or excellent by 85.3% of patients and 92.7% of researches. Conclusions: The results of this study demonstrate the efficacy of BTPc treatment with sublingual fentanyl in the context of the radiotherapy cancer treatment, with a significant decrease in VAS from baseline values??. The high satisfaction among physicians and patients with this treatment reflects the efficacy and convenience of sublingual fentanyl in controlling BTPc., Introducción: en el contexto de la radioterapia, el control del dolor irruptivo oncológico (DIO) supone un reto especial. El DIO ha sido definido por la Sociedad Española del Dolor (SED), la Sociedad Española de Oncología Médica (SEOM) y la Sociedad Española de Cuidados Paliativos (SECPAL) como una exacerbación del dolor súbita y transitoria, de gran intensidad (EVA > 7) y de corta duración (inferior a 20-30 minutos), que aparece sobre la base de un dolor persistente estable cuando este se encuentra reducido a un nivel tolerable (EVA < 5) mediante el uso de opioides mayores. Objetivos: el objetivo principal de este estudio fue evaluar la intensidad del DIO inducido por tratamientos oncológicos que incluyeran radioterapia (RT), tanto exclusiva como asociada a quimioterapia (RT/QT). Secundariamente, se evaluó la eficacia del tratamiento con fentanilo sublingual pautado para el control del DIO. Material y métodos: estudio observacional retrospectivo realizado en 110 pacientes reclutados en 19 Servicios de Radioterapia españoles. Los pacientes debían presentar DIO inducido por RT o RT/QT, con o sin medicación pautada y cuya intensidad fuera de una EVA > 6 en las últimas 24-48 h. Se establecieron controles en el momento basal, y a los 3, 7, 15 y 30 días. Resultados: se apreció un descenso en la media de los valores en la escala EVA según avanzó el estudio (EVA = 6 en el control 0 a EVA = 3 en el control 3), y las diferencias fueron significativas (p < 0,0001). La satisfacción con el tratamiento fue calificada como buena o excelente por el 85,3% de los pacientes y por el 92,7% de los investigadores. Conclusiones: los resultados de este estudio demuestran la eficacia del tratamiento del DIO con fentanilo sublingual en el contexto del tratamiento oncológico radioterápico, con un descenso significativo en los valores EVA frente al valor basal. La elevada satisfacción de los médicos y pacientes con este tratamiento refleja la eficacia y la comodidad del fentanilo sublingual e

Published
2015

47. 819P - Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide

Author

López Campos, F., Moreno, I., Conde-Moreno, A., Gómez-Iturriaga, A., Ruiz Vico, M., Romero Laorden, N., Henríquez López, I., Peleteiro Higuero, P., Lozano Mejorada, R., Piquer, T., Couselo, M., Gómez Ramos, J., Navarro, J., Barrionuevo Castillo, P., García, R., Villatoro, R., Montesa, A., Saez, M.I., Herrera, B., and Castro Marcos, E.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results